Loading stock data…
TMO
$486.83-7.24 (-1.47%)
Market OpenUpdated 12:25 PM EDT
Thermo Fisher Scientific Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Thermo Fisher Scientific Inc. in the Healthcare sector is trading at $486.83 with a market capitalization of $165.3B. Wall Street consensus targets $602.76 (25 analysts), implying a +23.8% move over the next 12 months. The stock is currently 24% below its 52-week high of $643.99, remaining 7.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.01B↓ | $12.21B↑ | $11.12B↑ | $10.85B↑ | $10.36B |
| Gross Profit | $4.43B↓ | $5.01B↑ | $4.58B↑ | $4.41B↑ | $4.24B |
| Operating Income | $1.91B↓ | $2.30B↑ | $2.08B↑ | $1.92B↑ | $1.81B |
| Net Income | $1.65B↓ | $1.96B↑ | $1.62B | $1.62B↑ | $1.51B |
Peer Comparison
JNJUNHPFE
Fundamentals
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four se...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$165.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.36%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.19%
Volume
Today's trading volume
561,656
Recent News
Wolfe Research Downgrades Danaher Corporation (DHR)
Danaher Corporation (NYSE:DHR) is one of the best healthcare stocks to buy with highest upside potential. Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is “a […]
Why HSBC Turned More Cautious on Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. (NYSE:TMO) is included among the Billionaire Ken Fisher’s Top 11 Dividend Stock Picks. On June 3, HSBC downgraded Thermo Fisher Scientific Inc. (NYSE:TMO) to Hold from Buy. It also lowered its price target on the stock to $540 from $670.The firm said Thermo Fisher’s goal of returning to 7% growth beyond […]
ICON Stock Valuation vs Peers: Is ICLR Cheap Enough?
ICLR looks cheap at 14.7x forward EPS versus peers, but 2026 guidance calls for lower revenue/EPS and a weak margin starting point.
ICLR Earnings Reset: What the Accounting Probe Changed
ICON plc details an accounting restatement, flags control weaknesses, and frames 2026 as a reset year amid mix-driven earnings swings.
The Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why
In late May 2026, Thermo Fisher Scientific showcased its new Thermo Scientific Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at the ASMS Conference, highlighting faster, more sensitive multiomics and complex drug development analysis alongside AI-enabled software and its Olink proteomics platform. By pairing these Orbitrap systems with recent AI-focused software acquisitions and expanded bioanalytical labs in Sweden, Thermo Fisher is deepening its role across the entire drug...